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Aims: Type 2 diabetes is a reported risk factor for more frequent and severe urinary tract infections (UTI).
We sought to quantify the annual healthcare cost burden of UTI in type 2 diabetic patients.
Methods: Adult patients diagnosed with type 2 diabetes were identiﬁed in MarketScan administrative claims
data.UTI occurrenceand costswereassessedduringa1-yearperiod.WeexaminedUTI-relatedvisit andantibiotic
costs among patients diagnosed with UTI, comparing those with versus without a history of UTI in the previous
year (prevalent vs. incident UTI cases). We estimated the total incremental cost of UTI by comparing all-cause
healthcare costs in patients with versus without UTI, using propensity score-matched samples.
Results:Within the year, 8.2% (6,014/73,151) of subjects had ≥1 UTI, of whom 33.8% had a history of UTI.
UTI-related costs among prevalent versus incident cases were, respectively, $603 versus $447 (p = 0.033)
for outpatient services, $1,607 versus $1,819 (p = NS) for hospitalizations, and $61 versus $35
(p b 0.0001) for antibiotics. UTI was associated with a total all-cause incremental cost of $7,045
(95% CI: 4,130, 13,051) per patient with UTI per year.
Conclusions: UTI is common and may impose a substantial direct medical cost burden among patients with
type 2 diabetes.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Type 2 diabetes is a chronic, progressive metabolic disorder
resulting from the loss of early insulin secretion and development of
insulin resistance (De Fronzo, 1999). In the United States, the
incidence of diabetes nearly tripled between 1990 and 2010, with
1.9 million new cases diagnosed in 2010 (Centers for Disease Control,
2013). Patients with type 2 diabetes are at an elevated risk of a
number of other medical conditions compared to non-diabetic
individuals, including cardiovascular disease, eye problems and
blindness, renal disease, and lower extremity amputations. Type 2
diabetes is also considered an immunocompromised state and is a
known risk factor for certain infectious diseases (Muller et al., 2005;
Shah & Hux, 2003).
Urinary tract infections (UTIs) are the most common type of
bacterial infections (Foxman, 2002). Asymptomatic bacteriuria andmMerck during the conduct of
erck stockholders; all authors
uct of the study.
+1 908 735 1688.
zf54@georgetown.edu (A.Z. Fu).
Inc. This is an open access article usymptomatic UTI are both reported to be more frequent in patients
with type 2 diabetes than in the general population (Hoepelman,
Meiland, & Geerlings, 2003; Ronald & Ludwig, 2001). Additional
evidence suggests that type 2 diabetes increases susceptibility to
serious complications of UTI, including emphysematous conditions of
the bladder or kidney, renal abscess, and renal papillary necrosis
(Grifﬁn, Bergstralhn, & Larson, 1995; Huang & Tseng, 2000; Mnif et al.,
2013). Atypical and resistant forms of infection may also be more
common in patients with type 2 diabetes (Stapleton, 2002). Several
different mechanisms may contribute to the higher frequency of UTI
and related complications among diabetic patients, including immune
function impairments (Delamaire et al., 1997; Muller et al., 2005),
dysfunctional bladder emptying related to autonomic neuropathy
(Hosking, Bennett, & Hampton, 1978; Truzzi, Almeida, Nunes, & Sadi,
2008), and higher glucose levels in the urine which may facilitate the
growth of pathogenic organisms (Chen, Jackson, & Boyko, 2009).
UTI imposes a substantial economic burden on the health system
(Foxman, 2002; Foxman, Barlow, D’Arcy, Gillespie, & Sobel, 2000);
nonetheless, formal evidence is limited on the direct medical cost
burden of UTI speciﬁcally among diabetic patients. Given the
increasing prevalence of type 2 diabetes and the clinical link between
diabetic status and UTI risk and severity, there is a need to understandnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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diabetes for resource allocation decisions in the U.S. Several large
observational studies have examined the risk of UTI in diabetic
populations; however, most have been restricted to female subjects
due to their signiﬁcantly higher risk of UTI compared to male patients
(Boyko, Fihn, Scholes, Abraham, & Monsey, 2005; Boyko et al., 2002;
Foxman, 2002). Other studies have measured the risk of UTI
among both men and women with diabetes in settings outside of
the U.S. (Al-Rubeann, Moharran, Al-Naqeb, Hassan, & Raﬁullah,
2013; Hirji, Guo, Andersson, Hammar, & Gomez-Caminero, 2012;
Muller et al., 2005).A recentUK-basedanalysis found that type2diabetes
increased UTI incidence for both men and women, but noted variation in
the relative risk across different gender and age groups (Hirji et al., 2012).
The study also found additional increases in UTI risk among diabetic
patients with longer duration of diabetes and among those with poor
glycemic control. Given differences in patient characteristics and health
care services between countries, additional population-based studies are
warranted to describe in detail the age- and gender-speciﬁc prevalence of
UTI among diabetic patients in the U.S.
Using a large retrospective analysis of commercial claims, we
sought to examine the rate of UTI among U.S. patients diagnosed with
type 2 diabetes in a managed care setting, and to estimate the
additional health care resource use and costs associated with the
occurrence and recurrence of UTI in the presence of type 2 diabetes.
2. Materials and methods
2.1. Data source
Data were obtained from the MarketScan Commercial Claims &
Encounters and the MarketScan Medicare Supplemental and Coordi-
nation of Beneﬁts databases covering the period from January 1, 2008
to September 9, 2011. The MarketScan databases are integrated, de-
identiﬁed, patient-level data sources representing the health services
of approximately 77 million individuals in all age groups since 1996,
drawn from 77 employers and 12 U.S. health plans, representing over
126 unique carriers. Enrollees include individuals with primary
coverage through fee-for-service or capitated health plans, including
comprehensive plans, exclusive provider organizations, preferred
provider organizations, point-of-service plans (with and without
capitation), and health maintenance organizations. All census regions
within the continental U.S. are represented in the database. Data
elements capture enrollment history, demographic information, and
claims for inpatient, outpatient and pharmacy services (including
prescriptions from mail-order and specialty pharmacies). All Market-
Scan data ﬁles are compliant with the patient conﬁdentiality
requirements of the Health Insurance Portability and Accountability
Act (HIPAA).
2.2. Sample selection
A random sampling of 5 million individuals with at least one
recorded diagnosis of type 2 diabetes (International Classiﬁcation of
Disease, 9th Revision, Clinical Modiﬁcation [ICD-9 CM]: 250.xx) were
drawn from the MarketScan database, and within the selected Market-
Scan population, those with a type 2 diabetes diagnosis between 2008
and 2009were randomly selected andused as the starting population of
the sample selection. This resulted in ~120,000 patients.
The study samplewas further restricted topatientswhowere at least
18 years old as of the start date, deﬁned as the ﬁrst type 2 diabetes
diagnosis date between 1/1/2008 and 9/30/2009, and continuously
enrolled in the database for a minimum of 2 years from the start date.
Patients were excluded if they had any diagnoses for type 1 diabetes
mellitus (ICD-9-CM: 250.x1, 250.x3) or other forms of secondary
diabetes (ICD-9-CM: 249.xx). Patients with an observed pregnancy
(ICD-9-CM: 630-679, V22) during their 2-year eligibility period werealso excluded from the analysis. The ﬁnal study sample consisted of
73,151 patients who met the inclusion/exclusion criteria.
2.3. Study design overview
The baseline and study periods were deﬁned respectively as the
ﬁrst and the second year following his/her start date. For each patient,
the occurrence of UTI events was separately determined using
diagnosis codes during the baseline and study period. Patients were
classiﬁed into two groups based on presence of UTI events during the
baseline period: prevalent cohort if he/she had a UTI event during the
baseline period and incident cohort if he/she did not have any UTI
event. Furthermore, among patients who had a UTI event during the
study period, those who also had a UTI event during the baseline
period were referred to as prevalent cases; otherwise incident cases.
The economic burden of UTIwas studied in both bottom-up and top-
down approaches. The bottom-up approach described UTI-related
health care utilization and cost outcomes among the patients with a
UTI event during the studyperiod bymeasuring health care services and
costs speciﬁcally associated with a UTI diagnosis code or an antibiotic
prescription for UTI in prevalent versus incident cases. The top-down
approach sought to comprehensively assess and compare any health
care service use associated with UTIs, including potential downstream
utilization and costs of UTI that may not be coded as UTI-related in the
database. We estimated the total incremental burden of UTI among
patientswith type2 diabetes by comparing all-cause utilization and cost
outcomes in patients with versus without UTI during the study period
using a matched sample. The matched sample consisted of the patients
with UTIs and their 1:1matched patients without UTIs using propensity
scorematching (PSM). Thematched adjusted analysis aimed toestimate
and compare incremental health care resource uses and cost in patients
with versuswithout a UTI event during the study period,whootherwise
had similar characteristics during the baseline period, such as: diagnosis
of UTI; hypoglycemia; microvascular complications (retinopathy/
blindness, neuropathy, nephropathy); cardiovascular conditions
(stroke, transient ischemic attacks, congestive heart failure, myocardial
infarction, ischemic heart diseases, peripheral arterial diseases); chronic
kidney diseases; and liver diseases.
2.4. Variable measurement
2.4.1. Exposure and covariates
AUTI eventwas identiﬁed in the database using ICD-9-CMdiagnosis
codes, including chronic pyelonephritis (590.0), acute pyelonephritis
(590.1), cystitis (595.x) and urinary tract infection, site not speciﬁed
(599.0). The study focused speciﬁcally on symptomatic UTI diagnoses
due to concerns that asymptomatic bacteriuria would be under-
diagnosed in retrospective claims data. Patient baseline characteristics
regarded as potential risk factors for UTI during the study period were
included as covariates, including age, gender, residential location
(rural vs. urban), census region, health plan type, Charlson Comorbidity
Index (CCI), hypoglycemia,microvascular complications, cardiovascular
conditions, chronic kidney diseases and liver diseases.
2.4.2. Outcome variables
Health care utilization and cost outcomesweremeasured.Utilization
outcome variables included hospitalizations, length of stay (in days),
outpatient visits and uses of antibiotics for UTI treatment. Hospital and
outpatient visitswere consideredUTI-related if theywere recordedwith
aUTI diagnosis code. UTI-related prescription drugswere deﬁned as any
antibiotic prescriptions ﬁlled no later than 7 days after a UTI diagnosis,
or within the supply days of a previous UTI-related antibiotic drug ﬁll. If
a patient had multiple UTI-related antibiotic ﬁlls, the days of supply for
each ﬁll were combined together to compute total days of supply.
Direct health care costs were disaggregated into hospital,
outpatient, and prescription drug costs. Each cost component was
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perspective (i.e., out-of-pocket spending), and combined total.
There was no inﬂation adjustment due to the short duration of the
study period.
2.5. Statistical analysis
The prevalence of UTI was calculated as the number of patients with
at least 1 UTI event during the study period, divided by the total number
of patients in the sample. This formula aligns with the deﬁnition of
period prevalence, or the proportion of individuals who have the
condition at any point during a period of time (Aschengrau & Seage,
2008). UTI prevalence was also stratiﬁed by gender and age groups.
Patient baseline characteristics were summarized for patients with
versus without UTI during the study period. For continuous variables,
the mean and standard deviation (SD) were reported; for binary and
categorical variables, proportions were reported. Between-group
differences were assessed using t- tests for continuous variables and
chi-square tests for categorical variables. In addition, the descriptive
analysis of baseline patient characteristics was conducted using the
entire study sample as well as the matched sample.
In the bottom-up approach that considered UTI-related utilizations
and costs, healthcare resource use was summarized by service type
among those who consumed the healthcare service. Differences in
resource use were assessed using t-tests for continuous variables and
chi-square tests for binary or categorical variables. Mean and standard
deviation of number of hospitalizations and total length of stay were
reported among patients with at least one UTI-related hospitalization
during the studyperiod. ThenumberofUTI-relatedoutpatient visitswas
summarized among patients with a least 1 UTI-related outpatient visit
during the study period. UTI-related prescription drug use was
summarized among those receiving antibiotics for UTIs, in terms of
the number of pharmacy claims and total number of days of supply
dispensed. For eachUTI-related cost component, themeanand standard
deviation were summarized among the patients who incurred the cost,
and UTI-related cost differences were assessed using t-tests.
In the top-down approach in which all-cause utilization and costs
were of interest, the mean and standard deviation were reported for all
patients in thematched sample. All-cause health care utilization and cost
outcomesduring the studyperiodwere comparedbetweenpatientswith
and without UTIs during the study period using t-tests for continuous
variables and chi-square tests for binary or categorical variables.
Propensity score matching was used for the comparison of all-
cause health care utilization and costs between patients with and
without UTI during the study period. Amultivariate logistic regression
model was used to estimate each subject's propensity (probability) of
having a UTI diagnosis in the study period, given his/her baseline
patient characteristics. Patients with UTI during the study periodwere
one-to-one matched with patients without UTIs using a greedy-
matching algorithm (Parsons, 2004). To adjust for residual differences
in baseline patient characteristics betweenmatched patients with and
without UTI, a generalized linear model with log link function and
gamma variance was used to compare total all-cause health care costs
between the matched groups (Diehr, Yanez, Ash, Hornbrook, & Lin,
1999). Upon the ﬁtting of the generalized linear model, the method of
recycled prediction was applied to estimate the total incremental cost
associated with a UTI during the study period (Basu & Rathouz, 2005).
3. Results
3.1. UTI prevalence
Of the ﬁnal sample of 73,151 patients, 6,014 (8.2%) were diagnosed
with a UTI during the study period. Stratiﬁed by gender, UTI was
diagnosed in 4,517 (12.9%) female patients and 1,497 (3.9%) male
patients. Fig. 1 further stratiﬁes the gender-speciﬁc prevalence of UTIby age category. While the prevalence of UTI in female patients
ﬂuctuated around 12.9% across the age categories, a steady increase in
the prevalence of UTI inmale patients can be seen as age increases. For
both male and female patients, there was a steep increase in the
prevalence of UTI from the age categories of 65–74 years to 75+
years. Female patients also showed a large increase in UTI prevalence
from the age groups of 18–24 years to 25–34 years.3.2. Patient characteristics during the baseline period
The overall prevalence of UTI during the baseline period was 8.5%,
similar to thatobservedduring the studyperiod. Two thousand thirty-two
(37.2%) patients with baseline UTIs developed UTIs during the study
period; 3,982 (5.95%) patients without baseline UTIs developed UTIs
during the study period (p b 0.0001).
Table 1 presents the comparison of baseline characteristics
between patients with and without UTI during the study period.
Females comprised 75.1% of patients with UTI versus 45.4% of those
without UTI (p b 0.0001) in the study period. Age distribution
signiﬁcantly differed between patients with and without UTI
(p b 0.0001), with a larger proportion of patients with UTI during
the study period falling into the age category of 25–34 year (1.6% vs.
1.3%) and 75 or older (22.5% vs. 15.8%) than controls. Overall
comorbidity, measured by Charlson Comorbidity Index, also tended
to be greater among those with UTI during the study period (1.024 vs.
0.710; p b 0.0001). Signiﬁcantly more patients with UTIs during the
study period also had hypoglycemia (4.2% vs. 3.1%; p b .0001),
diabetes-related microvascular complications (22.9% vs. 18.9%;
p b .0001), cardiovascular diseases (26.1% vs. 20.3%; p b .0001),
chronic kidney diseases (5.9% vs. 3.9%; p b .0001) and liver diseases
(2.7% vs. 1.9%; p b .0001).
After adjusting for other baseline covariates in the logistic
regression for UTI propensity, ages of 75+ years (odds ratio
[OR]: 1.30 vs. 55–64 years; 95% CI: 1.19, 1.42), female gender
(OR: 2.96; 95% CI: 2.78, 3.15), and presence of UTI during the
baseline period (OR: 5.70; 95% CI: 5.34, 6.08) continued to be
the strongest predictors of UTI in the study period (results
not shown).3.3. UTI-related health care resource use and costs
Table 2 reports UTI-related utilization and cost outcomes in the
prevalent versus incident cases. Approximately 10% of patients in
either group had at least one UTI-related hospitalization during the
study period. Among the hospitalized, mean length of stay per visit
was 7.58 days (SD: 15.2) and 7.25 days (SD: 17.8) for the prevalent
and incident cases, respectively (p = 0.81). Nearly all prevalent and
incident cases had at least one UTI-related outpatient visit in the study
period, but the proportion was signiﬁcantly greater among prevalent
cases (97.5% vs. 95.1%; p b 0.0001). The total number of UTI-related
outpatient visits was also signiﬁcantly higher in prevalent versus
incident cases (2.38 vs. 1.56; p b 0.0001). Antibiotic treatment for UTI
was more common in prevalent than incident cases (66.1% vs. 62.3%;
p = 0.003), and antibiotic users in prevalent cases tended to have
more pharmacy claims for antibiotic drugs (4.79 vs. 3.21; p b 0.0001)
and longer days of supply (67.1 vs. 30.9; p b 0.0001) than those in
incident cases.
On average, prevalent cases incurred signiﬁcantly higher total
costs of UTI-related outpatient services ($603 vs. $447; p = 0.033)
and antibiotic prescriptions ($61 vs. $35; p b 0.0001) than incident
cases. The cost of UTI-related inpatient services was higher in the
prevalent cases than the incident cases; however, the cost differences
was not statistically signiﬁcantly between the two groups ($2,271 vs.
$2,301; p = NS).
18-24 25-34 35-34 45-54 55-64 65-74 75+
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(N=38,132) 1.6% 2.8% 2.4% 2.7% 3.6% 4.3% 6.8%
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Fig. 1. Prevalence of UTI within 1-year study period, by gender and age group.
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Six thousand and nine patients (out of 6,014) with UTI in the study
period were matched to those without UTI during the study period
based on the estimated propensity scores. No signiﬁcant difference in
baseline patient characteristics was detected after matching. Table 3
presents the matched comparison of total utilization and cost
outcomes. In this matched analysis, patients with UTI had signiﬁcantly
more outpatient visits during the study period (24.47 vs. 17.77;
p b 0.0001), a higher risk of hospitalization (26.73% vs. 12.66%;
p b 0.0001), and longer duration of stays per hospitalization (1.99 vs.
0.71 days; p b 0.0001).
On average, patients with UTI in the study period incurred total
annual hospitalization costs of $6,389 compared to $2,730 for
matched patients without UTI (incremental cost: $3,659;
p b 0.0001). Those with UTI also spent an additional $2,864 on
outpatient services (p b 0.0001) and an additional $243 on prescrip-
tion drugs (p b 0.0001) per patient per year, relative to those without
UTI. Overall, all-cause health care spending by patients with and
without UTI was, respectively, $19,562 and $12,796, for a difference of
$6,766 (p b 0.0001).
Applying the method of recycled predictions based on the results
of multivariable cost analysis, the incremental costs associated with
UTI was estimated to be $7,045 (95% CI: 4,130–13,051; p b 0.0001)
per patient with type 2 diabetes per year (results not shown).
4. Conclusions
This study examined the 1-year prevalence and health care cost
implications of UTI in a large sample of adult U.S. patients diagnosed
with type 2 diabetes. Overall, we observed an 8.2% risk of one or more
UTI diagnoses during a year-long study period. Although female
gender was a strong predictor of UTI risk, UTI was commonly
diagnosed in both men (3.9%) and women (12.9%) with type 2diabetes. The 1-year UTI prevalence of 8.2% in this study was higher
than the 0.0469/patient–year incidence rate reported for UK patients
with type 2 diabetes (Hirji et al., 2012), and the 7.0% prevalence
reported for Dutch patients with type 2 diabetes (Muller et al., 2005).
The higher frequency of UTI in our study could reﬂect true differences
in UTI risk between diabetic patients in each country, but could also be
due to differences in the comprehensiveness of the database used. The
UK and Dutch studies relied on primary care medical records, which
may not systematically capture UTIs diagnosed in a hospital or
specialist setting.
To our knowledge, this study is the ﬁrst to estimate the total direct
health care cost burden of UTI speciﬁcally among patients with type 2
diabetes, a group that is predisposed to a more complicated course of
UTI (Mnif et al., 2013). One recent claims database analysis reported
median antibiotic treatment costs of $10 and $8, respectively, per
diabetic and non-diabetic woman with at least one UTI during a 2-year
period (Stellhorn, Chow,Martin, &Mehra, 2013). Yet the estimate omits
the expense of UTI-related hospitalizations and outpatient visits, which
we found to be larger cost drivers than antibiotics. On average,
hospitalization cost was the largest UTI-related cost component
among diabetic patients with UTI, even though less than 10% of these
patients had a UTI-related hospitalization. Prior evidence suggests that
diabetesmaybe a risk factor forworseoutcomes inpatients hospitalized
withUTI (Benﬁeld, Jensen, &Nordestgaard, 2007; de Lastours&Foxman,
2014; Kofteridis et al., 2009; Pertel & Haverstock, 2006). For example, in
a case–control study of elderly patients hospitalized for acute
pyelonephritis in Greece, diabetes was associated with signiﬁcantly
longer lengths of stay and higher risks of bacteremia complications and
mortality (Kofteridis et al., 2009).
Findings from this study suggest a high cost burden of UTI among
patients diagnosed with type 2 diabetes. Across all cost components,
UTI-related health care cost over 1 year was approximately $2,300 per
type 2 diabetes patient diagnosed with UTI, a ﬁgure that reﬂects
observed payments for claimswith a UTI diagnosis code or an antibiotic
Table 1
Baseline characteristics of type 2 diabetes patients with versus without UTI diagnosis
during study period.
Baseline factors With UTI in
study period
(N = 6,014)
Without UTI in
study period
(N = 67,137)
p-value
Age (years), mean (SD) 62.5 (13.6) 60.5 (12.4) b0.0001
Age group (years), n (%)
18–24 9 (0.2%) 132 (0.2%) b0.0001
25–34 96 (1.6%) 856 (1.3%)
35–44 399 (6.6%) 4,769 (7.1%)
45–54 1,130 (18.8%) 15,007 (22.4%)
55–64 2,211 (36.8%) 26,047 (38.8%)
65–74 814 (13.5%) 9,712 (14.5%)
75+ 1,355 (22.5%) 10,614 (15.8%)
Female, n (%) 4,517 (75.1%) 30,502 (45.4%) b0.0001
Rural (vs. urban), n (%) 989 (16.5%) 11,530 (17.2%) 0.15
Residential location, n (%)
Northeast 458 (7.6%) 5,819 (8.7%) b0.0001
North central 1,688 (28.1%) 20,057 (29.9%)
South 2,692 (44.8%) 27,885 (41.5%)
West 1,155 (19.2%) 13,269 (19.8%)
Unspeciﬁed 21 (0.4%) 107 (0.2%)
Health plan type, n (%)
Comprehensive 1,151 (19.6%) 11,237 (17.1%) b0.0001
HMO 975 (16.6%) 11,717 (17.9%)
POS 396 (6.8%) 5,622 (8.6%)
PPO 3,157 (53.8%) 34,616 (52.7%)
Other⁎ 186 (3,1%) 2,438 (3.6%)
Charlson comorbidity index,
mean (SD)
1.024 (1.597) 0.710 (1.316) b0.0001
Comorbidities, n (%)
Urinary tract infections (UTIs) 2,032 (33.8%) 4,158 (6.2%) b0.0001
Hypoglycemia 250 (4.2%) 2,050 (3.1%) b0.0001
Microvascular complications 1,379 (22.9%) 12,718 (18.9%) b0.0001
Retinopathy/Blindness 417 (6.9%) 4,679 (7.0%) 0.92
Neuropathy 718 (11.9%) 5,912 (8.8%) b0.0001
Nephropathy 450 (7.5%) 3,871 (5.8%) b0.0001
Cardiovascular conditions 1,568 (26.1%) 13,640 (20.3%) b0.0001
Stroke 138 (2.3%) 863 (1.3%) b0.0001
Transient ischemic attacks 139 (2.3%) 875 (1.3%) b0.0001
Congestive heart failure 385 (6.4%) 2,608 (3.9%) b0.0001
Myocardial infarction 123 (2.1%) 1,197 (1.8%) 0.14
Ischemic heart diseases
(incl. angina)
1,007 (16.7%) 9,803 (14.6%) b0.0001
Peripheral arterial diseases 419 (7.0%) 3,157 (4.7%) b0.0001
Chronic kidney diseases 352 (5.9%) 2,583 (3.9%) b0.0001
Liver diseases 164 (2.7%) 1,295 (1.9%) b0.0001
⁎ Other health plans include exclusive provider organizations, point of service with
capitation, consumer-directedhealthplans, andhighdeductiblehealth plans.HMO,health
maintenance organization. POS, point of service. PPO, preferred provider organization.
Table 2
UTI-related health care utilization and cost among type 2 diabetes patients with UTI
diagnosis during study period (n = 6,014).
UTI-related utilization and
costs during 1-year study period
With baseline
UTI (n = 2,032)
Without baseline
UTI (n = 3,982)
p-value
Utilization
≥1 Hospitalizations during
study period, n (%)
194 (9.55%) 393 (9.87%) 0.69
Number of hospitalizations,
mean (SD)
1.113 (0.38) 1.112 (0.60) 0.97
Length of stay per
hospitalization, mean (SD)
7.58 (15.2) 7.250 (17.8) 0.81
≥1 Outpatient visits during
study period, n (%)
1,981 (97.49%) 3,785 (95.05%) b0.0001
Number of outpatient
visits, mean (SD)
2.38 (3.06) 1.56 (1.58) b0.0001
Use of antibiotics for UTI
treatment, n (%)
1,343 (66.09%) 2,479 (62.26%) 0.003
Number of ﬁlls per patient–year,
mean (SD)
4.8 (4.40) 3.2 (2.31) b0.0001
Total days of supply, mean (SD) 67.1 (131.9) 30.9 (57.0) b0.0001
Overall costs to payers and
patients, mean (SD)
Total costs 2,271 (11,318) 2,301 (13,792) 0.93
For inpatient services 1,607 (10,770) 1,819 (13,480) 0.51
For outpatient services 603 (2,874) 447 (2,271) 0.033
For pharmaceutical drugs 61 (137) 35 (115) b0.0001
Costs to payers, mean (SD)
Total costs 2,162 (11,251) 2,200 (13,665) 0.91
For inpatient services 1,574 (10,709) 1,778 (13,357) 0.52
For outpatient services 549 (2,848) 401 (2,240) 0.041
For pharmaceutical drugs 39 (110) 21 (103) b0.0001
Costs to patients, mean (SD)
Total costs 109 (263) 101 (270) 0.26
For inpatient services 32 (217) 41 (237) 0.16
For outpatient services 54 (132) 46 (123) 0.019
For pharmaceutical drugs 23 (41) 14 (24) b0.0001
625S. Yu et al. / Journal of Diabetes and Its Complications 28 (2014) 621–626drug code following a UTI diagnosis. Beyond UTI-related costs, the total
incremental health care costs attributable toUTIwere over $7,000 in the
matched comparison of diabetic patients with and without UTI. Using
either approach, our estimates of annual cost per type 2 diabetes patient
with UTI are notably high in comparison to previous estimates of UTI's
costs in the general U.S population. Foxman et al. (Foxman et al., 2000)
estimated the direct medical cost burden of UTI to be $474 million in
1995 among an estimated 11.3 million women with UTI, amounting to
$42 per patient with UTI per year (Foxman et al., 2000). Aside from the
difference in study populations, the higher costs in our study are partly
explained by inﬂation, health care cost growth, and potential secular
trends in themanagement of UTI since 1995. The differencemay also be
driven bydifferences in researchmethods and assumptions. Of note, the
1995 estimate was derived using amicro-costingmodel that multiplied
the expected annual number of outpatient visits and antibiotic drug ﬁlls
by a unit cost; the model did not consider inpatient service costs, and
assumed a maximum of one UTI event per patient per year. In contrast,
the present study beneﬁted from actual cost data recorded in study
subjects' inpatient, outpatient, and prescription drug claims and may
provide amore complete summary of costs that are associatedwithUTI.In accordance with prior studies (de Lastours & Foxman, 2014;
Ribera et al., 2006), diabetic patients with a history of UTI faced a
signiﬁcantly greater burden in terms of their subsequent UTI risk. We
also detected differences in the annual utilization and cost burden of
UTI depending on whether or not the patient had a recent history of
UTI. Namely, UTI sufferers with a baseline history of UTI had more
frequent UTI-related outpatient visits and antibiotic drug ﬁlls during
the study period than those without a history of UTI. These ﬁndings
may reﬂect a higher number of distinct UTI events during the year
among those with a prior history of infection. It is also possible that
patients with a history of UTI had more severe UTI episodes, or were
more vigilant in seeking medical care when UTI symptoms occurred.
This study is subject to several limitations. Identiﬁcation of UTI
events was based on recorded diagnoses in claims, and would not
capture any UTI events for which the patient never sought care or was
able to treat with a previously-obtained antibiotic supply. Conse-
quently, our estimates of UTI rates, utilization, and costs reﬂect that of
UTIs diagnosed by a provider, which are probably more symptomatic
and costlier than UTIs that go undiagnosed. Similarly, because type 2
diabetes was identiﬁed by diagnosis codes, study results apply
speciﬁcally to patients with diagnosed type 2 diabetes and may not
generalize to undiagnosed diabetic patients. Calculations of UTI-
related utilization and costs rely on the accuracy and completeness of
the provider's coding, and may not include all relevant costs resulting
from UTI. The comparison of all-cause utilization and costs between
diabetic patients with and without UTI adjusted for a variety of
demographic and baseline health factors available in claims; however,
the analysis may still be subject to confounding from unobserved
variables, including disease duration and glycemic control. In
estimating the cost burden of UTI, this study focused exclusively on
direct medical expenses incurred by the insurer and the patient. A
Table 3
All-cause health care utilization and cost among 1:1 matched type 2 diabetes patients
with vs. without UTI diagnosis during study period.
All-cause utilization and cost
during 1-year study period
With UTI in
study period
(N = 6,009)
Without UTI in
study period
(N = 6,009)
p-value
Utilization
≥1 Hospitalizations
during study period, n (%)
1606 (26.73%) 761 (12.66%) b0.0001
Number of
hospitalizations, mean (SD)
0.371 (0.764) 0.163 (0.500) b0.0001
Total length of stay per
patient–year, mean (SD)
1.989 (8.762) 0.710 (3.094) b0.0001
≥1 Outpatient visits during
study period, n (%)
6,009 (100.00%) 5,951 (99.03%) b0.0001
Number of outpatient
visits, mean (SD)
24.47 (20.47) 17.77 (17.44) b0.0001
Use of antibiotics for
UTI treatment, n (%)
5,838 (97.15%) 5,787 (96.31%) 0.009
Number of ﬁlls per
patient–year,
mean (SD)
43.4 (32.0) 37.5 (29.0) b0.0001
Overall costs to payers
and patients, mean (SD)
Total costs 19,562 (34,948) 12,796 (26,331) b0.0001
For inpatient services 6,389 (24,743) 2,730 (12,236) b0.0001
For outpatient services 9,479 (17,874) 6,615 (19,350) b0.0001
For pharmaceutical drugs 3,694 (4,606) 3,451 (4,613) 0.004
Costs to payers, mean (SD)
Total costs 1,667 (1,472) 1,358 (2,899) b0.0001
For inpatient services 150 (527) 84 (514) b0.0001
For outpatient services 833 (976) 654 (2,475) b0.0001
For pharmaceutical drugs 684 (660) 621 (589) b0.0001
Costs to patients, mean (SD)
Total costs 17,895 (34,434) 11,437 (25,260) b0.0001
For inpatient services 6,239 (24,555) 2,645 (12,059) b0.0001
For outpatient services 8,646 (17,582) 5,962 (18,473) b0.0001
For pharmaceutical drugs 3,010 (4,237) 2,830 (4,313) 0.021
626 S. Yu et al. / Journal of Diabetes and Its Complications 28 (2014) 621–626complete assessment of societal cost burden would also need to
consider the indirect costs of UTI, including work loss costs due to
medical visits and UTI-related disability.
In conclusion, UTI was common and caused substantially higher
costs of care in a large sample of U.S. patients diagnosed with type 2
diabetes. Given the steadily increasing prevalence of type 2 diabetes,
increased attention should be paid to preventing and managing UTI
among patients with type 2 diabetes.Acknowledgments
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